| PHILADELPHIA, May 21, 2020 /PRNewswire/ -- Carisma Therapeutics Inc. a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present and take meetings at upcoming virtual healthcare investor conferences in May and June 2020. - 6th Annual Digital Immuno-Oncology Innovation Forum, May 26-27, 2020:
- Carisma will take meetings and Steven Kelly, CEO, will present virtually on May 27, 2020, at 11:00 am EST. The presentation will be accessible via a live webcast.
- Jefferies Healthcare Conference, June 2-4, 2020:
- Carisma will take meetings and Steven Kelly, CEO, will present virtually on June 3, 2020, at 4:00 pm EST. The presentation will be accessible via a live webcast.
- BIO Digital, June 8-12, 2020:
- Carisma will take meetings for the duration of the digital conference.
- Xcelerating Life Sciences: Becoming the Cell & Gene Therapy Hub, June 11, 2020:
- Michael Klichinsky, Co-founder and Vice President of Discovery Research, will present virtually on June 11, 2020, at 2:00 pm EST. The presentation will be accessible via a live webcast.
About Carisma Therapeutics Inc. Carisma Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com To schedule investor meetings with Carisma Therapeutics, please contact: Kara Collins 215-847-3440 kara.collins@carismatx.com View original content:http://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-and-meet-with-potential-investors-at-upcoming-healthcare-investor-conferences-301063696.html SOURCE Carisma Therapeutics Inc. | |